Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 94 citing articles:

Bruton tyrosine kinase inhibitors for multiple sclerosis
Julia Krämer, Amit Bar‐Or, Timothy J. Turner, et al.
Nature Reviews Neurology (2023) Vol. 19, Iss. 5, pp. 289-304
Open Access | Times Cited: 99
BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies
Aqu Alu, Hong Lei, Xuejiao Han, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 86
Regulatory Mechanism of M1/M2 Macrophage Polarization in the Development of Autoimmune Diseases
Yuan Peng, Mengxian Zhou, Yang Hong, et al.
Mediators of Inflammation (2023) Vol. 2023, pp. 1-20
Open Access | Times Cited: 66
Protein kinases: drug targets for immunological disorders
Leslie Castelo‐Soccio, Hanna Kim, Massimo Gadina, et al.
Nature reviews. Immunology (2023) Vol. 23, Iss. 12, pp. 787-806
Open Access | Times Cited: 55
Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials
Dariusz Rozkiewicz, Justyna Magdalena Hermanowicz, Iwona Kwiatkowska, et al.
Molecules (2023) Vol. 28, Iss. 5, pp. 2400-2400
Open Access | Times Cited: 46
Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives
Ewa Robak, Tadeusz Robak
Journal of Clinical Medicine (2022) Vol. 11, Iss. 10, pp. 2807-2807
Open Access | Times Cited: 47
Targeting B cells and plasma cells in autoimmune diseases: From established treatments to novel therapeutic approaches
Ana Merino‐Vico, Giulia Frazzei, Jan Piet van Hamburg, et al.
European Journal of Immunology (2022) Vol. 53, Iss. 1
Open Access | Times Cited: 47
Future landscape for the management of membranous nephropathy
Fernando Caravaca‐Fontán, Federico Yandián, Fernando C. Fervenza
Clinical Kidney Journal (2023) Vol. 16, Iss. 8, pp. 1228-1238
Open Access | Times Cited: 24
Sequential immunotherapy: towards cures for autoimmunity
Francisco Ramírez‐Valle, Joseph Maranville, Sophie Roy, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 7, pp. 501-524
Closed Access | Times Cited: 10
Epigenetic regulation of B cells and its role in autoimmune pathogenesis
Fan Xiao, Ke Rui, Xiaofei Shi, et al.
Cellular and Molecular Immunology (2022) Vol. 19, Iss. 11, pp. 1215-1234
Open Access | Times Cited: 36
BTK signaling—a crucial link in the pathophysiology of chronic spontaneous urticaria
Jonathan A. Bernstein, Marcus Maurer, Sarbjit S. Saini
Journal of Allergy and Clinical Immunology (2023) Vol. 153, Iss. 5, pp. 1229-1240
Open Access | Times Cited: 19
Efficacy and Safety of Upadacitinib or Elsubrutinib Alone or in Combination for Patients With Systemic Lupus Erythematosus: A Phase 2 Randomized Controlled Trial
Joan T. Merrill, Yoshiya Tanaka, David D’Cruz, et al.
Arthritis & Rheumatology (2024)
Open Access | Times Cited: 7
BTK inhibitors: past, present, and future
Allison Cool, Tiffany Nong, Skye Montoya, et al.
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 8, pp. 691-707
Closed Access | Times Cited: 7
Interferon and B-cell Signatures Inform Precision Medicine in Lupus Nephritis
Ioannis Parodis, Julius Lindblom, Daniel Toro‐Domínguez, et al.
Kidney International Reports (2024) Vol. 9, Iss. 6, pp. 1817-1835
Open Access | Times Cited: 6
Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review
Óscar Fernández, Per Soelberg Sørensen, Gıancarlo Comı, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
A review of Bruton’s tyrosine kinase inhibitors in multiple sclerosis
Laura Airas, Robert Bermel, Tanuja Chitnis, et al.
Therapeutic Advances in Neurological Disorders (2024) Vol. 17
Open Access | Times Cited: 6
Discovery and Preclinical Characterization of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK Inhibitor for the Treatment of Multiple Sclerosis
Martin Himmelbauer, Bekim Bajrami, Rebecca Basile, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 10, pp. 8122-8140
Open Access | Times Cited: 6
Targeting autoimmune mechanisms by precision medicine in Myasthenia Gravis
Paola Cavalcante, Renato Mantegazza, Carlo Antozzi
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
Medicinal Chemistry Strategies for the Development of Bruton’s Tyrosine Kinase Inhibitors against Resistance
Shan‐Liang Sun, Shi-Han Wu, Ji-Bo Kang, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 11, pp. 7415-7437
Closed Access | Times Cited: 27
Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren’s syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial
Thomas Dörner, Martin Kaul, Antónia Szántó, et al.
Annals of the Rheumatic Diseases (2023) Vol. 83, Iss. 3, pp. 360-371
Open Access | Times Cited: 15
Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Current Therapeutic Approaches and Future Outlooks
Yusuf A. Rajabally
ImmunoTargets and Therapy (2024) Vol. Volume 13, pp. 99-110
Open Access | Times Cited: 5
Bruton's tyrosine kinase inhibition for the treatment of allergic disorders
Erica V. Lin, Ragha Suresh, Melanie C. Dispenza
Annals of Allergy Asthma & Immunology (2024) Vol. 133, Iss. 1, pp. 33-42
Open Access | Times Cited: 5
Current therapeutic strategies and perspectives in refractory ITP: What have we learned recently?
Yue Lv, Huiping Shi, Hong Liu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 22
Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib
David Yin-wei Lin, Amy H. Andreotti
PLoS ONE (2023) Vol. 18, Iss. 8, pp. e0290872-e0290872
Open Access | Times Cited: 12
Design and application of a fluorescent probe for imaging of endogenous Bruton’s tyrosine kinase with preserved enzymatic activity
Anna P. Valaka, Helena Filipsson Nyström, Liliana Håversen, et al.
RSC Chemical Biology (2025)
Open Access
Page 1 - Next Page

Scroll to top